Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 106 for:    alanine | Non-Alcoholic Steatohepatitis

A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03468556
Recruitment Status : Not yet recruiting
First Posted : March 16, 2018
Last Update Posted : December 5, 2018
Sponsor:
Information provided by (Responsible Party):
Sinew Pharma Inc.

Brief Summary:
The primary objective of the study is to compare the changes in serum ALT level among patients with non-alcoholic steatohepatitis (NASH) following 3-month treatment of 800 mg SNP-610 or the placebo. The secondary objectives will be to compare the changes in liver fat fraction, other liver function tests, cytokeratin-18 (CK-18) fragment level and adverse event / serious adverse event rates among the interventional and placebo arms.

Condition or disease Intervention/treatment Phase
NASH - Nonalcoholic Steatohepatitis Drug: SNP-610 Drug: Placebo Oral Tablet Phase 2

Detailed Description:

A randomized, double-blind, placebo controlled study will be conducted in medical centers around Taiwan.

The objective of the study is to investigate the efficacy and safety of SNP-610 for the treatment of NASH, assuming the treatment efficacy of the investigational product is superior to the placebo control.

Subjects who fulfill all the entry criteria and have written informed consent will be enrolled to the study. Eligible subjects will be randomized in a 1:1 ratio to receive study drug or placebo control. Considering a 10% drop-out rate, approximately 80 subjects will be enrolled in order to recruit 70 evaluable subjects, each arm will be at least 35 evaluable subjects to complete the enrollment.

Subjects will be administered the test drugs or placebo oral daily for 3 months or until treatment terminates prematurely. Subjects will return to the study center for clinical evaluation once every 4 weeks throughout the treatment period. Clinical assessment procedures and laboratory tests including ultrasound imaging, hematology with differential, biochemistry, liver function panel, and urinalysis, will be performed at each study visit. The primary endpoint assessment will be the reduction of ALT at completion of Week 12 treatment.

Subjects who finish treatment or discontinue prematurely from the study for any reason after receiving one or more doses of study drug will be assessed for safety for 2 (±1) weeks after the last study drug dose or longer in the case of any significant AE or abnormal biochemical or clinical finding.

Each subject will participate in the study for approximately 14 weeks (including the enrollment/baseline visit, 3 routine monthly visits during treatment period, and 1 follow-up visit after 2 weeks of the end of treatment).

It is assumed the study will include a 6 months enrollment period and a further 4 months to complete the follow-up for all enrolled patients.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: test drug
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: placebo
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
Estimated Study Start Date : June 1, 2019
Estimated Primary Completion Date : June 30, 2019
Estimated Study Completion Date : June 30, 2019


Arm Intervention/treatment
Experimental: test drug
2 tabs of SNP-610
Drug: SNP-610
Subjects will take 2 tablets once a day orally for 12 weeks

Placebo Comparator: placebo
2 tabs of placebo
Drug: Placebo Oral Tablet
Subjects will take 2 tablets once a day orally for 12 weeks




Primary Outcome Measures :
  1. Alanine aminotransferase [ Time Frame: 12 weeks ]
    Absolute change from baseline in serum alanine aminotransferase (ALT/GPT)


Secondary Outcome Measures :
  1. MRI liver FF [ Time Frame: 12 weeks ]
    Absolute change from baseline in liver fat content

  2. MRI liver FF [ Time Frame: 12 weeks ]
    Relative change from baseline in liver fat content

  3. Aspartate aminotransferase [ Time Frame: 12 weeks ]
    Change in serum level at 12 weeks

  4. Alkaline phosphatase [ Time Frame: 12 weeks ]
    Change in serum level at 12 weeks

  5. Gamma-glutamyl transpeptidase [ Time Frame: 12 weeks ]
    Change in serum level at 12 weeks

  6. Total bilirubin [ Time Frame: 12 weeks ]
    Change in serum level at 12 weeks

  7. Galactose single point [ Time Frame: 12 weeks ]
    Change in serum level at 12 weeks

  8. CK-18 [ Time Frame: 12 weeks ]
    Change in serum level at 12 weeks


Other Outcome Measures:
  1. Insulin resistance [ Time Frame: 12 weeks ]
    Change in insulin resistance at Week 12

  2. Triglycerides [ Time Frame: 12 weeks ]
    Changes in serum at Week 12

  3. Low density lipoprotein [ Time Frame: 12 weeks ]
    Changes in serum at Week 12

  4. Total cholesterol [ Time Frame: 12 weeks ]
    Changes in serum at Week 12

  5. High density lipoprotein [ Time Frame: 12 weeks ]
    Changes in serum at Week 12

  6. Gene expression biomarkers [ Time Frame: 12 weeks ]
    Gene expression biomarkers (ACC1, Adfp, AOX, Cat, CCL20, CCR2, Cpt1α, CYP2E1, CYP4A11, CYP7A, Dgat1, Dgat2, FAS, Gapdh, Gpx1, Gpx2, Gpx3, Gpx4, GSS, Hadh, Ho1, HSL, IL-10, IL-1β, IL-6, iNOS, LCAD, NF-κB1, NF-κB2, Pparα, PPARβ/δ, PPARγ, SCD-1, Sod1, Sod2, Sod3, SREBP-1c, TGFβ, TLR4, TNFα, Ucp2, VLCAD, α-SMA, β-actin) related to NASH changes in blood at Week 12

  7. Rate of patients who experience AEs leading to discontinuation at end of treatment [ Time Frame: 12 weeks ]
  8. Rate of patients who experience AE/SAE at end of treatment [ Time Frame: 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 20 years
  2. Body weight ≥ 54 kg
  3. Diagnosis of non-alcoholic steatohepatitis (NASH) as evidenced by imaging or other diagnostic assessments. Subject should have documented liver fat content ≥ 10.0 % as measured by MRI method prior to study drug administration.
  4. Alanine aminotransferase (ALT) levels ≥ 2.0x upper limit of normal (ULN) on at least two occasions, seven or more days apart, prior to study drug administration
  5. Have adequate organ functions as defined by the following examinations prior to the start of study treatment:

    1. Hematology: Hemoglobin ≥ 9 g/dL, a platelet count ≥ 100 x 10^9/L, and a white blood cell count ≥ 3.0 x 10^9/L
    2. Renal: creatinine clearance ≥ 90 mL/min (by Cockcroft-Gault equation), serum uric acid < 9.0 mg/dL
  6. Able to provide written informed consent, and understand and comply with the requirements of the study

Exclusion Criteria:

  1. Decompensated or severe liver disease as evidenced by one or more of the following:

    1. Confirmed cirrhosis or suspicion of cirrhosis
    2. Liver transplant
    3. Liver malignancy
    4. Ascites
    5. Bilirubin >2 x ULN, or ALT or AST > 10 x ULN
    6. Acute or chronic hepatitis A, B, C, HIV, or other liver diseases affecting liver function.

    Patients with cysts, hemangiomas, or similar abnormalities, are accepted.

  2. History or presence of alcohol abuse, defined as consumption of more than 210 mL of alcohol per week (the equivalent of 14 glasses of 120-mL wine or 14 cans of 350-mL beer), or other substance abuse within the prior two years
  3. Subjects who are unable to undergo an MRI scan.
  4. Subjects have electronically, magnetically and mechanically activated implanted devices, including but not limited to automatic cardioverter defibrillators, cardiac pacemakers, insulin pumps, metallic splinters in the eye, ferromagnetic haemostatic clips in central nervous systems or vascular vessels.
  5. Significant systemic or major illness other than liver disease, including auto-immune disease, coronary artery disease, cerebrovascular disease, malignant neoplasms, pulmonary disease, renal insufficiency, serious psychiatric disease, and/or other serious disease, that, in the opinion of the Investigator would preclude the subject from participating in and completing the study
  6. Documented history of serious allergic reaction to SNP-610 or any structurally related compounds
  7. Diabetic patients who have not maintained a stable dose of oral medication for hyperglycemia or have had more than 10 percent change in their insulin dose over the past two months
  8. Regular use of agents that are potent against hepatitis or affecting lipid metabolisms, including but not limited to HMGCoA reductase inhibitors (statins), fibrates, silymarin, N-acetylcysteine, or anti-TNF therapies.

    Note: refer to Section 6.5 Prohibited agents for details.

  9. Pregnant or lactating
  10. Female of child-bearing potential who are not committed to take reliable contraception during the participation of the study and at least 4 weeks after the end of the study treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03468556


Contacts
Layout table for location contacts
Contact: Chen-Che Su, MS 0910633800 h2243398@sinewpharma.com

Sponsors and Collaborators
Sinew Pharma Inc.

Layout table for additonal information
Responsible Party: Sinew Pharma Inc.
ClinicalTrials.gov Identifier: NCT03468556     History of Changes
Other Study ID Numbers: SNP-610-201
First Posted: March 16, 2018    Key Record Dates
Last Update Posted: December 5, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Fatty Liver
Non-alcoholic Fatty Liver Disease
Liver Diseases
Digestive System Diseases